Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.

Ezogabine has gained approval as an adjunctive treatment for focal-onset seizures in patients aged 18 and older. Its efficacy in enhancing seizure control makes it a valuable addition to the armamentarium of antiepileptic drugs. However, its use was discontinued in 2017 in the US due to concerns about its safety.

The drug's oral administration offers convenience for patients and healthcare providers alike. Furthermore, it boasts rapid absorption following administration, ensuring a swift onset of action.

Ezogabine undergoes metabolism through processes such as glucuronidation and acetylation. This intricate metabolic pathway contributes to its pharmacokinetic profile. The drug exhibits a half-life spanning 7 to 11 hours, indicating its suitability for maintaining therapeutic levels in the bloodstream.

Both ezogabine and its metabolites are primarily excreted through the urine, offering a predictable route of elimination.

As with many medications, ezogabine is associated with various adverse effects, although not all patients may experience them. Common side effects include dizziness, drowsiness, fatigue, confusion, and blurred vision. These effects may impact a patient's daily activities and should be monitored closely.

In addition to the common adverse effects, ezogabine has been associated with other potential side effects, such as vertigo, diplopia, and memory impairment. Notably, neuropsychiatric symptoms, including suicidal thoughts and behavior, have been reported in some individuals. The U.S. Food and Drug Administration (FDA) has issued warnings about the risks of these serious adverse effects, some of which may have long-lasting consequences.

Del capítulo 17:

article

Now Playing

17.8 : Antiepileptic Drugs: Potassium Channel Activators

Pharmacotherapy of the Epilepsies

51 Vistas

article

17.1 : Arterias de las extremidades inferiores

Pharmacotherapy of the Epilepsies

111 Vistas

article

17.2 : Convulsiones: Clasificación

Pharmacotherapy of the Epilepsies

186 Vistas

article

17.3 : Fármacos antiepilépticos: bloqueadores de los canales de sodio

Pharmacotherapy of the Epilepsies

78 Vistas

article

17.4 : Fármacos antiepilépticos: potenciadores de la vía GABAérgica

Pharmacotherapy of the Epilepsies

167 Vistas

article

17.5 : Fármacos antiepilépticos: bloqueadores de los canales de calcio

Pharmacotherapy of the Epilepsies

78 Vistas

article

17.6 : Fármacos antiepilépticos: antagonistas del glutamato

Pharmacotherapy of the Epilepsies

157 Vistas

article

17.7 : Fármacos antiepilépticos: moduladores de la liberación de neurotransmisores mediados por la proteína SV2A

Pharmacotherapy of the Epilepsies

105 Vistas

JoVE Logo

Privacidad

Condiciones de uso

Políticas

Investigación

Educación

ACERCA DE JoVE

Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados